Dosing & Uses
Cutaneous T-Cell Lymphoma
Reformulated product pending FDA approval for treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL)
Next:
Pharmacology
Mechanism of Action
Recombinant fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments; specifically binds to IL-2 receptors on cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
